Potential Impact And Cost-Effectiveness Of Future ETEC And Shigella Vaccines In 79 Low- And Lower Middle-Income Countries

ASU Author/Contributor (non-ASU co-authors, if there are any, appear on document)
Richard Rheingans Ph.D., Department Chair (Creator)
Institution
Appalachian State University (ASU )
Web Site: https://library.appstate.edu/

Abstract: While diarrhea mortality in children has declined over the last two decades, there has been a slower decline in diarrheal episodes. Repeated diarrheal episodes are associated with childhood stunting, which leads to increased mortality risk from infectious diseases. Vaccine candidates are under development for enterotoxigenic Escherichia coli [ETEC] and Shigella, important enteric pathogens in children in low income countries. These future vaccines could significantly reduce diarrheal burden, prevent ETEC-and Shigella-induced stunting, and stunting-associated mortality. We developed a cost-effectiveness model for two putative standalone ETEC and Shigella vaccine candidates to evaluate vaccine impact on mortality, morbidity, stunting, and stunting-associated deaths from other infectious diseases. We modeled impact over the first ten years after vaccine introduction in children under five years old living in 79 low and low-middle income countries.

Additional Information

Publication
Anderson IJD, Bagamian KH, Muhib F, et al. Potential impact and cost-effectiveness of future ETEC and Shigella vaccines in 79 low- and lower middle-income countries. Vaccine: X. 2019;2. doi:10.1016/j.jvacx.2019.100024. Publisher version of record available at: https://www.sciencedirect.com/science/article/pii/S2590136219300257
Language: English
Date: 2019
Keywords
ETEC, Shigella, Diarrhea, Stunting, Cost-effectiveness, Vaccines

Email this document to